|Bid||49.60 x 18700|
|Ask||49.62 x 15000|
|Day's Range||49.28 - 49.70|
|52 Week Range||38.53 - 55.25|
|PE Ratio (TTM)||32.87|
|Earnings Date||May 15, 2018|
|Forward Dividend & Yield||0.55 (1.11%)|
|1y Target Est||49.55|
Today I will examine Carl Zeiss Meditec AG’s (XTRA:AFX) latest earnings update (31 December 2017) and compare these figures against its performance over the past couple of years, in additionRead More...
Categories: Yahoo FinanceGet free summary analysis Carl Zeiss Meditec AG reports financial results for the year ended September 30, 2017. We analyze the earnings along side the following peers of Carl Zeiss Meditec AG – Draegerwerk AG & Co. KGaA, Geratherm Medical AG and Eckert & Ziegler Strahlen- und Medizintechnik AG (DRW8-DE, GME-DE and EUZ-DE) that have ... Read more (Read more...)
Valeant Pharmaceuticals International Inc said it would sell its iNova Pharmaceuticals business for $930 million, as Chief Executive Officer Joseph Papa steps up efforts to slash the embattled Canadian drugmaker's huge debt pile. The company's U.S.-listed shares were up about 3.5 percent at $12.60 in premarket trading on Thursday.
Canadian drugmaker Valeant Pharmaceuticals International Inc is in talks to sell its Bausch & Lomb unit's surgical products business to Germany's Carl Zeiss Meditec AG, Bloomberg reported. Valeant's eye-surgery assets may be valued at about $2 billion in a sale, Bloomberg reported, citing people familiar with the matter. "We don't comment on speculation or rumors," Valeant spokeswoman Lainie Keller said in an email.
Categories: Yahoo FinanceGet free summary analysis Carl Zeiss Meditec AG reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Carl Zeiss Meditec AG – Draegerwerk AG & Co. KGaA and Eckert & Ziegler Strahlen- und Medizintechnik AG (DRW8-DE and EUZ-DE) that have also reported for this ... Read more (Read more...)